IGFBP-5 ELISA

RUO

AL-127

INTENDED USE

The Total IGFBP-5 enzyme linked immunosorbent assay (ELISA) kit provides materials for the quantitative measurement of IGFBP-5 in human serum and other biological fluids. This kit is intended for laboratory research use only and is not for use in diagnostic or therapeutic procedures.

SUMMARY AND EXPLANATION

Insulin-like growth factor binding protein 5 (IGFBP-5) is part of the IGF-binding proteins that regulates IGF activity by binding to IGF ligands. The IGF axis consists of six high-affinity IGF-binding proteins (IGFBP 1-6). IGFBP-5 has 272 amino acids and weighs about 31 kDa. IGF axis is the principal endocrine system that regulates the differentiation, development, and maintenance of bone tissue. Dysfunction of this axis is associated with various skeletal pathologies such as growth disorders and abnormal bone structure.[1,2]

Pregnancy-Associated Plasma Protein-A2 (PAPP-A2) plays a major role in bone cell physiology as well. PAPP-A2 is also known to proteolyze IGFBP-5. Certain mutation in the PAPP-A2 protein inhibits its ability to proteolyze IGFBP-5. Consequently, affected individuals show microcephaly, mild BMD effects and thin long bones. Thus, IGFBP-5 plays an important role in osteoblast differentiation and bone tissue metabolism which remains to be further expounded upon.[1,2]

PRINCIPLE OF THE TEST

The IGFBP-5 ELISA is a quantitative two-step sandwich type immunoassay. In the first step, Calibrators, Controls and unknown diluted samples are added to IGFBP-5 antibody coated microtiter wells and incubated. After the first incubation and washing step, the wells are incubated with horseradish peroxidase labelled antibody conjugate. After a second incubation and washing step, the wells are incubated with substrate solution (TMB). After TMB incubation, an acidic stopping solution is added. In principle, the antibody-HRP conjugate binds to the solid phase antibody-antigen complex. Finally, the antibody-antigen and conjugate complex bound to the well is detected by addition of enzyme-substrate reaction. The degree of enzymatic turnover of the substrate is determined by dual wavelength absorbance measurement at 450 nm as primary test filter and 630 nm as reference filter. The absorbance measured is directly proportional to the concentration of IGFBP-5 in the samples and calibrators.

MATERIALS SUPPLIED

CAL-127A IGFBP-5 Calibrator A

One vial, 2.5 mL, labeled IGFBP-5 Cal A, containing 0 ng/mL IGFBP-5 in protein based buffer and Pro-Clean 400. Store unopened at 2-8°C until the expiration date.

CAL-127B – CAL-127F IGFBP-5 Calibrators B – F (Lyophilized)

Five vials, labeled B-F, containing concentrations of approximately 15-1200 ng/mL IGFBP-5 in protein based buffer and Pro-Clean 400. Refer to **calibration card** for exact concentrations. Store unopened at 2 to 8°C until the expiration date. **Reconstitute calibrators B-F with 0.5 mL deionized water**. Solubilize, Mix well and use after reconstitution. Aliquot and freeze in plastic vials immediately for multiple use and discard after the run. Avoid repeated freeze thaws. The IGFBP-5 concentration in the IGFBP-5 calibrators is traceable to the manufacturer's working calibrators. Values assigned by other methodologies may be different. Such differences, if present, may be caused by inter-method bias.

CTR-127-I & CTR-127-II IGFBP-5 Controls I & II

Two vials, labeled Levels I and II containing low and high IGFBP-5 concentrations in protein based buffer and Pro-Clean 400. Refer to **calibration card** for exact concentrations. Store unopened at 2 to 8°C until the expiration date. **Reconstitute control Levels I and II with 0.5 mL deionized water.** Solubilize, Mix well and use after reconstitution. Aliquot and Freeze immediately in plastic vials for multiple use and discard after run. Avoid repeated freeze thaws.

PLT-127 IGFBP-5 Coated Microtitration strips

One stripholder, containing 12 strips and 96 microtitration wells with IGFBP-5 antibody immobilized to the inside wall of each well. Store at 2-8°C until expiration date in the resealable pouch with a desiccant to protect from moisture.

ASB-127 IGFBP-5 Assay Buffer

One bottle, 12 mL with a non-mercury preservative. Store at 2-8°C until expiration date.

ECR-127 IGFBP-5 Antibody-Enzyme Conjugate RTU

One amber bottle, 12 mL, containing IGFBP-5 antibody conjugated to HRP in a protein buffer with a non-mercury preservative. Store at 2 to 8°C until the expiration date.

TMB-100 TMB Chromogen Solution

One bottle, 12 mL, containing a solution of tetramethylbenzidine (TMB) in buffer with hydrogen peroxide. Store at 2-8°C until expiration date.

STP-100 Stopping Solution

One bottle, 12 mL, containing 0.2 M sulfuric acid. Store at 2 to 30°C until expiration date.

WSH-100 Wash Concentrate A

One bottle, 60 mL, containing buffered saline with a nonionic detergent. Store at 2-30°C until expiration date. Dilute 25-fold with deionized water prior to use.

MATERIALS REQUIRED BUT NOT PROVIDED

1. Microtitration plate reader capable of absorbance measurement at 450 nm, 405nm and 630 nm.
2. Microplate orbital shaker.
3. Microplate washer.
4. Semi-automated/manual precision pipette to deliver 10–250 µL.
5. Repeator pipette.

6. Vortex mixer.
7. Deionized water.

WARNINGS AND PRECAUTIONS

For Research Use Only. Not for use in diagnostic procedures.

The following precautions should be observed:

a) Follow good laboratory practice.
b) Use personal protective equipment. Wear lab coats and disposable gloves when handling immunoassay materials.
c) Handle and dispose of all reagents and material in compliance with applicable regulations

WARNING: Potential Biohazardous Material

This reagent may contain some human source material (e.g. serum) or materials used in conjunction with human source materials. Handle all reagents and patient samples at a Biosafety Level 2, as recommended for any potentially infectious human material in the Centers for Disease Control/National Institutes of Health manual "Biosafety in Microbiological and Biomedical Laboratories," 5th Edition, 2007[3].

WARNING: Potential Chemical Hazard

Some reagents in this kit contain Pro-Clean 400 and Sodium azide[4] as a preservative. Pro-Clean 400 and Sodium azide in concentrated amounts are irritants to skin and mucous membranes.

For further information regarding hazardous substances in the kit, please refer to the MSDS, either at AnshLabs.com or by request.

SAMPLE COLLECTION AND PREPARATION

a) Serum is the recommended sample type.
b) Sample handling, processing, and storage requirements depend on the brand of blood collection tube that you use. Please reference the manufacturer's instructions for guidance. Each laboratory should determine the acceptability of its own blood collection tubes and serum separation products.
c) Samples may be stored at 4°C if assayed within 24 hours, otherwise samples must be stored at -20°C or -80°C to avoid loss of bioactivity and contamination.
d) Avoid assaying lipemic, hemolyzed or icteric samples.
e) Avoid repeated freezing and thawing of samples. Thaw samples no more than 3 times.
f) For shipping, place specimens in leak proof containers in biohazard specimen bags with appropriate specimen identification and test requisition information in the outside pocket of the biohazard specimen bag. Follow DOT and IATA requirements when shipping specimens.

PROCEDURAL NOTES

1. A thorough understanding of this package insert is necessary for successful use of the IGFBP-5 ELISA assay. It is the user's responsibility to validate the assay for their purpose. Accurate results will only be obtained by using precise laboratory techniques and following the package insert.
2. A calibration curve must be included with each assay.
3. Bring all kit reagents to room temperature (23 ± 2°C) before use. Thoroughly mix the reagents before use by gentle inversion. Do not mix various lots of any kit component and do not use any component beyond the expiration date.
4. Use a clean disposable pipette tip for each reagent, calibrator, control or sample. Avoid microbial contamination of reagents, contamination of the substrate solutions with the HRP conjugates. The enzyme used as the label is inactivated by oxygen, and is highly sensitive to microbial contamination, sodium azide, hypochlorous acid and aromatic chlorohydrocarbons often found in laboratory water supplies. Use deionized water.
5. Incomplete washing will adversely affect the outcome and assay precision. Care should be taken to add TMB into the wells to minimize potential assay drift due to variation in the TMB incubation time. Avoid exposure of the reagents to excessive heat or direct sunlight.

PREPARATION OF REAGENTS

1. **IGFBP-5 calibrators B-F and IGFBP-5 Controls I & II**: Tap and reconstitute IGFBP-5 Calibrator B-F and IGFBP-5 Controls I & II each **with 0.5 mL deionized water**. Solubilize, mix well and use after reconstitution.
2. **Wash Solution:** Dilute wash concentrate **25-fold with deionized water**. The wash solution is stable for one month at room temperature (23 ± 2°C) when stored in a tightly sealed bottle.
3. **Microtitration Wells:** Select the number of coated wells required for the assay. The remaining unused wells should be placed in the resealable pouch with a desiccant. The pouch must be resealed to protect from moisture.

ASSAY PROCEDURE

Allow all specimens and reagents to reach room temperature (23 ± 2°C) and mix thoroughly by gentle inversion before use. Calibrators, controls, and unknowns should be assayed in duplicate.

Note: Do not dilute the calibrators and controls. *All samples reading higher than the highest calibrator should be diluted in the 0 ng/mL Calibrator A prior to assay.*

1. Reconstitute IGFBP-5 Calibrator B-F and IGFBP-5 Controls I & II each with **0.5 mL deionized water** as mentioned in the **Preparation of Reagents** section. Solubilize for **10 minutes**, Mix well by gentle vortex.
2. Label the microtitration strips to be used.
3. Pipette **20 µL** of the **Calibrator, Controls and Unknowns** to the appropriate wells
4. Add **100 µL** of the IGFBP-5 Assay Buffer to each well using a repeater pipette.
5. Incubate the plate, shaking at a fast speed (**600-800 rpm**) on an orbital microplate shaker, for 6**0 minutes** at room temperature (23 ± 2°C).
6. Aspirate and wash each strip **5 times** with Wash Solution **(350 µL/per well)** using an automatic microplate washer.
7. Add **100 µL** of the IGFBP-5 Enzyme Conjugate Solution to each well using a repeater pipette.
8. Incubate the plate, shaking at a fast speed (**600-800 rpm**) on an orbital microplate shaker, for **60 minutes** at room temperature (23 ± 2°C).
9. Aspirate and wash each strip **5 times** with the Wash Solution **(350 µL/per well)** using an automatic microplate washer.
10. Add **100 µL** of the TMB chromogen solution to each well using a repeater pipette. Avoid exposure to direct sunlight.
11. Incubate the wells, shaking at **600–800 rpm** on an orbital microplate shaker, for **8-12 min** at room temperature (23 ± 2°C).
    NOTE: Visually monitor the color development to optimize the incubation time.
12. Add **100 µL** of the stopping solution to each well using a repeater pipette. Read the absorbance of the solution in the wells within **20 minutes**, using a microplate reader set to **450 nm**.
13. ***NOTE****: Zero calibrator should be programmed as "**Blank**" while reading the optical density. If instrument has a wavelength correction, set the instrument to dual wavelength measurement at **450 nm** with background wavelength correction at **630 nm**.*

RESULTS

NOTE: *The results in this package insert were calculated by plotting the* ***log optical density (OD) data on the y-axis and log IGFBP-5 concentration on X-axis*** *using a cubic regression curve-fit. Alternatively, log vs. log quadratic regression curve-fit can be used. Other data reduction methods may give slightly different results.*

1. Optimum results can be obtained at incubation temperature of **(23 ± 2°C)**.
2. Calculate the mean optical density (OD) for each calibrator, Control, or Unknown.
3. Plot the log of the mean OD readings for each of the Calibrators along the y-axis versus log of the IGFBP-5 concentrations in ng/mL along the x-axis, using a cubic regression curve-fit.
4. Determine the IGFBP-5 concentrations of the Controls and unknowns from the calibration curve by matching their mean OD readings with the corresponding IGFBP-5 concentrations.
5. Any sample reading higher than the highest Calibrator should be appropriately diluted with the 0 ng/mL (CAL A / Sample Diluent) and re-assayed.
6. Any sample reading lower than the analytical sensitivity should be reported as such.

LIMITATIONS

The reagents supplied in this kit are optimized to measure IGFBP-5 levels in human serum. If there is evidence of microbial contamination or excessive turbidity in a reagent, discard the vial. For assays employing antibodies, the possibility exists for interference by heterophile antibodies in the samples.[5]

QUALITY CONTROL

- Each laboratory should establish mean values and acceptable ranges to assure proper performance.
- IGFBP-5 ELISA controls or other commercial controls should fall within established confidence limits.
- The confidence limits for IGFBP-5 controls are printed on the **Calibration card**.
- A full calibration curve, low and high level controls, should be included in each assay.
- TMB should be colorless. Development of any color may indicate reagent contamination or instability.

REPRESENTATIVE CALIBRATION CURVE DATA

Well Number	Well Contents	Mean Absorbance	Conc (ng/mL)
A1, A2	**Calibrators** A	0.074 (Blank)	0
B1, B2	B	0.062	15.3
C1, C2	C	0.216	56.8
D1, D2	D	0.469	132.5
E1, E2	E	1.23	406.7
F1, F2	F	2.404	902

CAUTION*: The above data must not be employed in lieu of data obtained by the user in the laboratory*

ANALYTICAL CHARACTERISTICS

All analytical characteristics are stated in ng/mL.

Analytical Specificity:

The monoclonal antibody pair used in the assay detects IGFBP-3. Other related analytes at 1000 ng/mL did not show any cross-reaction.

Sample No.	Cross-reactant	Concentration (ng/mL)	% Cross-reactivity
1	IGF-I	1000	ND
2	IGFBP-2	1000	ND
3	IGFBP-4	1000	ND
4	IGFBP-3	1000	ND
5	Rat IGF-I	1000	ND
7	IGF-II	1000	ND

Linearity:

Two serum samples and F calibrator were used for dilution.

Sample	Dilution Factor	Expected Conc. (ng/mL)	Observed Conc. (ng/mL)	% Recovery
1	Neat	223.1	NA	NA
	1: 2	111.55	113.0	101%
	1: 4	55.775	51.8	93%
	1:8	27.888	24.6	88%
2	Neat	181.5	NA	NA
	1: 2	90.75	81.9	90%
	1: 4	45.375	37.7	83%
	1:8	22.688	19.4	86%
F Calibrator	Neat	831.2	NA	NA
	1: 2	415.6	474.2	114%
	1: 4	207.8	226.4	109%
	1:8	103.9	111.9	108%

Interference:

When potential interferents (hemoglobin, biotin, intralipids, and bilirubin) were added at least at two times their physiological concentration to control sample, IGFBP-5 concentrations were within ± 15% of the control as represented in the following table.

Interferent	Interferent Dose	Analyte Conc. (ng/mL)	Spiked Sample Value (ng/mL)	% Difference
Hemoglobin	1 mg/mL	323.5	349.8	8.1
	0.5 mg/mL	350.1	358.7	2.5
	0.1 mg/mL	371.1	363.6	-2.0
Biotin	1200 ng/mL	348.0	326.7	-6.1
	600 ng/mL	350.8	316.8	-9.7
Intralipids	20 mg/mL	361.6	363.1	0.4
	10 mg/mL	355.1	317.2	-10.7
	5 mg/mL	306.3	343.4	12.1
Bilirubin	0.66 mg/mL	238.2	257.3	8.0
	0.2 mg/mL	312.4	321.0	2.8

Expected Values:

The expected ranges for IGFBP-5 in pediatric male samples in the age range of 3.0 – 18.0 years were calculated using 95% non-parametric estimation. A total of 402 samples in Pubic Hair Tanner stages 1 - 5 were evaluated using Analyse-It® for Microsoft Excel as seen in table below.

Male Reference Intervals (IGFBP-5)			
Pubic Hair Tanner Stage	**No of specimens (n)**	**Median Conc. (ng/mL)**	**IGFBP-5 (ng/mL) 95% CI**
1	216	329.8	235.4 - 649.9
2	54	373.1	264.4 - 919.5
3	32	436.0	278.4 - 698.9
4	50	487.9	318.4 - 786.2
5	50	465.1	337.6 - 1067.1

The expected ranges for IGFBP-5 in pediatric female samples in the age range of 2.4 – 18.0 years were calculated using 95% non-parametric estimation. A

total of 433 samples in Breast Tanner stages 0 - 5 were evaluated using Analyse-It® for Microsoft Excel as seen in table below.

Female Reference Intervals (IGFBP-5)			
Breast Tanner Stage	**No of specimens (n)**	**Median Conc. (ng/mL)**	**IGFBP-5 (ng/mL) 95% CI**
0	15	335.9	237.5 - 608.2
1	174	372.4	250.1 - 702.5
2	61	427.5	282.7 - 738.7
3	58	501.9	310.6 - 756.3
4	54	486.7	335.6 - 701.0
5	71	455.3	281.9 - 789.9

40 human serum samples were analyzed using Ansh Labs IGFBP-5 ELISA. The expected ranges were calculated using 95% non-parametric estimation in the IGFBP-5 ELISA kit using Analyse-It® for Microsoft Excel as seen in table below.

Sample	**n**	**Age Range**	**Median Conc. (ng/mL)**	**IGFBP-5 (ng/mL) 95% CI**
Male	15	20 - 54 years	367.4	172.4 - 708.7
Female	15	23 - 55 years	418.3	144.7 - 1008.1
PM	10	71 - 81 years	383.7	242.2 - 418.3

REFERENCES

1. Beattie et al. Insulin- like Growth Factor-Binding Protein Action in Bone Tissue: A Key Role for Pregnancy- Associated Plasma Protein-A. Front. Endocrinol., 2018
2. Duan, Cunming, and John B Allard. "Insulin-Like Growth Factor Binding Protein-5 in Physiology and Disease." *Frontiers in endocrinology* vol. 11 100. 3 Mar. 2020, doi:10.3389/fendo.2020.00100
3. HHS Publication, 5th ed., 2007. Biosafety in Microbiological and Biomedical Laboratories. Available http://www.cdc.gov/biosafety/publications/bmbl5/BMBL5
4. DHHS (NIOSH) Publication No. 78–127, August 1976. Current Intelligence Bulletin 13 - Explosive Azide Hazard. Available http:// www.cdc.gov/niosh.
5. Kricka L. Interferences in immunoassays – still a threat. Clin Chem 2000; 46: 1037–1038.

FOR RESEARCH USE ONLY

Not for use in diagnostic procedures.

Manufactured by:
Ansh Labs
445 Medical Center Blvd.
Webster, TX 77598-4217, U.S.A.